Navigation Links
Merit Medical Pre-Announces Record Sales and Earnings for the Second Quarter Ended June 30, 2008
Date:7/10/2008

SOUTH JORDAN, Utah, July 10 /PRNewswire-FirstCall/ -- Merit Medical Systems, Inc. (Nasdaq: MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology and radiology procedures, announced today that sales for the second quarter ended June 30, 2008 were approximately $57.4 million, an increase of 11% over the second quarter of 2007, which the Company believes will produce earnings in the range of $0.19-$0.21 per share for the quarter. Gross margins for the second quarter are estimated to be approximately 42.7%, which would result in an increase of 500 basis points from the second quarter of 2007.

The Company cautioned that these estimates are unaudited and are subject to modification or revision in the course of completing the Company's quarter- end financial review and audit of the Company's financial results.

Full details and final results will be reported at 4:00 p.m. Eastern Time on Wednesday, July 23rd, 2008. Merit's management will hold a conference call to discuss the specifics the same day (July 23rd) at 5:00 p.m. ET. The telephone numbers to call are (domestic) 800-218-9073; and (international) 303-205-0033. A live webcast will also be available for the conference call at http://www.merit.com and http://www.fulldisclosure.com . The webcast will be archived on both sites.

ABOUT MERIT

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology and radiology. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 90 individuals. Merit employs approximately 1,600 people worldwide, with facilities in Salt Lake City and South Jordan, Utah; Angleton, Texas; Richmond, Virginia; Maastricht and Venlo, The Netherlands; and Galway, Ireland.

Statements contained in this release, which are not purely historical, are forward-looking statements within the meaning of the Private Securities Litigation Act of 1995 and are subject to risks and uncertainties such as those described in Merit's Annual Report on Form 10-K for the year ended December 31, 2007. Such risks and uncertainties include product recalls and product liability claims; infringement of Merit's technology or the assertion that Merit's technology infringes the rights of other parties; termination of relationship with suppliers, or failure of suppliers to perform; inability to successfully manage growth through acquisitions; delays in obtaining regulatory approvals, or the failure to maintain such approvals; concentration of Merit's revenues among a few products and procedures; development of new products and technology that could render Merit's products obsolete, market acceptance of new products, introduction of products in a timely fashion, price and product competition, availability of labor and materials, cost increases, and fluctuations in and obsolescence of inventory; volatility of the market price of Merit's common stock; foreign currency fluctuations; key personnel; work stoppage or transportation risks; modification or limitation of governmental or private insurance reimbursement, changes in health care markets related to health care reform initiatives; and other factors referred to in Merit's Annual Report on Form 10-K and other reports filed with the Securities and Exchange Commission. All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results may differ materially from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and Merit assumes no obligation to update or disclose revisions to those estimates.


'/>"/>
SOURCE Merit Medical Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Verus Pharmaceuticals Announces Divestiture of Pediatric GI Development Program to Meritage Pharma
2. Rutgers College of Nursings Linda Flynn to receive N.J. Governors Nursing Merit Award
3. Six Receive Associations Award of Meritorious Achievement
4. Merit Medical Systems Announces Earnings Release Date/Time and Conference Call Information for the First Quarter Ended March 31, 2008
5. Amigo Mobility Selects Amerityre as OEM Supplier
6. Merit Medical Systems Announces Earnings Release Date/Time and Conference Call Information for the Year Ended December 31, 2007
7. Siemens Financial Services, Inc. Announces Completion of Credit Facility With Merit Mountainside, LLC
8. Rutgers College of Nursing emerita professor Beverly Whipple receives FSSS book award
9. Meritain Health Announces Name Change for Acquired Companies
10. NOTES research activities increase with grants from Olympus medical Systems totaling $1 million
11. SmoothToe Diabetic Socks Acquired by Lifestyle Medical Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... ... century approach to infusing high speed technology into the fabric of an entire ... the advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere ... Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is ... of providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... joined the Peoples Health network on Dec. 1, 2016. Peoples Health, a Metairie-based ... Medical Center is an exciting addition to our provider network, and the addition ...
(Date:1/17/2017)... ... 2017 , ... A prescription medication bottle, pocket knife, luggage and a solar-powered ... Product Design Challenge , the Cradle to Cradle Products Innovation Institute has ... scheduled to run through early 2018. The challenges are presented by the Institute in ...
(Date:1/17/2017)... Livingston, NJ (PRWEB) , ... January 17, 2017 , ... ... services and financial planning assistance to communities throughout the region, is launching a charity ... , Heart disease is by far the deadliest killer in America, and is responsible ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... BALTIMORE , Jan. 17, 2017 Paragon ... to provide product development services for a variety ... Diseases (NIAID) medical product development activities. The ... a contractor pool for task order awards up ... global leader in manufacturing and process development of ...
(Date:1/17/2017)... Management to Discuss Acquisition of Oncology ... On Track For An NDA Submission to ...   ... KTOV ; TASE: KTOV), an innovative biopharmaceutical company, announced that it will ... Eastern Time to discuss the recent acquisition of a majority stake in TyrNovo, ...
(Date:1/17/2017)... Jan. 17, 2017  Jazz Pharmaceuticals plc (Nasdaq: ... been enrolled in a Phase 3 clinical trial comparing ... care (BSC) in the prevention of hepatic veno-occlusive disease ... cell transplant (HSCT) who are at high risk or ... clinical trial will be conducted across approximately 100 medical ...
Breaking Medicine Technology: